Medical inquiries

Phone: +41 (0)41 767 7255

Mon - Fri 09.00 - 17.00

Email: medinfo.switzerland@bms.com

Websites for your patients

Useful disease information for your patients in a patient-friendly language:

BMS Events

Interested in attending a round table event or learning about BMS' presence at congresses? Check out our events section for information on past and upcoming events in various therapy areas.

 

 

BMSplus – the portal for health care professionals

 

Our Range of Topics at a Glance
 

image
Extensive media library

Access a wide range of resources, including webinars, podcasts, HCP materials, and patient brochures, all designed to support your professional needs.

 

image
Clinical data

 

image
Events and Congresses

 

image
Clinical Research

 

image
Your BMS team

 

Dive into our disease areas: explore resources, research, and insights

 

 

News and recent approvals

 

Icons
Gastrointestinal Cancer

January 2025 - OPDIVO® in combination with YERVOY® is now approved for the first-line treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) unresectable or metastatic colorectal cancer.

Icons
Thoracic Cancer

December 2024 - OPDIVO® in combination with YERVOY® and 2 cycles of platinum-based chemotherapy is now approved for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults with no EGFR or ALK genomic tumor aberrations.

More information

 

 

Icons
Genitourinary Cancer

August 2024 - OPDIVO® is now approved in combination with cisplatin/gemcitabine chemotherapy for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma with PD-L1 tumor expression ≥1%.

More information

Icons
Gastrointestinal Cancer

March 2024 – OPDIVO® (nivolumab) in combination with chemotherapy containing oxaliplatin and fluoropyrimidine is indicated for the first-line treatment of adult patients with inoperable, locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, and distal oesophageal adenocarcinoma with Combined Positive Score (CPS) PD-L1 expression ≥ 10.

More information

 

 

Icons
Melanoma

Februar 2024 – OPDUALAG® (nivolumab/relatlimab) is now reimbursed for the first-line treatment of adults with metastatic melanoma with PD-L1 < 1% expression.

www.spezialitaetenliste.ch

More information

Icons
Melanoma

November 2023 – Q4W 480 mg dosing with OPDIVO® (nivolumab) is approved in all melanoma indications.

Q4W dosing is approved for all Nivolumab monotherapy as well as monotherapy maintenance after Nivolumab + Ipilimumab combination treatment in melanoma.

More information

 

 

 

 

 

01/2025 ONC-CH-2500001